Switching from Saxenda to Wegovy: how the change works

Reviewed 7 sourcesPublished by PepVault

Switching from Saxenda to Wegovy: what both FDA labels say, when the first weekly shot goes in, which dose starts, and what switching studies found on weight.

Silver-haired man in a light-blue shirt rides a sage-green city bike along a riverside path
Last reviewed
Sources
7
Questions
7
Compounds
2

The short answer

Neither label sets a switching schedule, so the prescriber decides, and the two are never used together. A type 2 diabetes expert consensus times the first weekly Wegovy shot for when the next daily Saxenda dose would have been due, the day after the last. Wegovy's label starts at 0.25 mg for four weeks, then steps up every four. In STEP 8, semaglutide lost 15.8% of body weight, liraglutide 6.4%.

Every number checked at its primary source · · 7 sources · How we research

Evidence: One randomised head-to-head trial (STEP 8) compared the drugs from a fresh start; switching itself rests on one small randomised trial in type 2 diabetes, one retrospective obesity cohort and an expert consensus written for diabetes, plus the two FDA labels.

Silver-haired man in a light-blue shirt rides a sage-green city bike along a riverside path

Can you switch from Saxenda to Wegovy?

Yes. Both come from Novo Nordisk and both are FDA-approved for weight. Saxenda is liraglutide, injected once a day. Wegovy is semaglutide, injected once a week. Both are GLP-1 receptor agonists: they act on the receptor for GLP-1, a gut hormone that turns appetite down and slows the stomach12.

Neither label has a section on coming from another drug. Saxenda's label never mentions switching, and the only switch Wegovy's label describes is between its own injection and its own tablets12. What both say is that each is not used together with any other GLP-1 drug12. So the switch is a stop and a start, never an overlap, and its timing and first dose are the prescriber's call. This is the US labelling as of November 2026 (DailyMed: Saxenda, June 15, 2026; Wegovy, June 30, 2026).

The American College of Physicians' living guideline, last updated in April 2026, ranks semaglutide and tirzepatide as first-line weight treatments for adults with obesity and liraglutide as third-line, and it names switching after an inadequate response as a discussion between clinician and patient about benefits, harms, cost and goals7.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

In PepVault, finishing the Saxenda protocol keeps every daily dose on file, and a new Wegovy protocol set to once weekly gets its own dose time and reminder, so the nudge moves from every day to shot day.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Why do people switch from Saxenda to Wegovy?

An expert consensus on switching, written for type 2 diabetes, lists the usual reasons: more weight loss wanted, trouble keeping up with dosing, side effects, cost and coverage4. STEP 8, the one trial that put the two head to head, randomly assigned 338 US adults with overweight or obesity and no diabetes to weekly semaglutide 2.4 mg or daily liraglutide 3.0 mg, with diet and activity counselling, for 68 weeks3.

STEP 8, at 68 weeksWegovy (semaglutide 2.4 mg, weekly)Saxenda (liraglutide 3.0 mg, daily)
Average weight change−15.8%3−6.4%3
Lost 10% or more70.9%325.6%3
Lost 15% or more55.6%312.0%3
Lost 20% or more38.5%36.0%3
Stopped treatment, any reason13.5%327.6%3
Any stomach side effect84.1%382.7%3
Climb to the full dose16 weeks34 weeks3
A week strip: seven daily Saxenda shots, one on each day, against one Wegovy shot on day 1
Saxenda is a shot every day; Wegovy is one shot on the same day each week.

STEP 8 compared the two from a fresh start: each person took one drug, and nobody switched3. The Saxenda label adds its own checkpoint: an adult who has not lost at least 4% of starting weight 16 weeks in stops Saxenda, since lasting weight loss is unlikely1.

How soon after the last Saxenda dose does Wegovy start?

Neither label times it12. The timing people meet comes from an expert consensus on switching between GLP-1 drugs: in its authors' practice, the first dose of the new drug goes in when the next dose of the old one would have been due4. For daily Saxenda, that is the day after the last dose. Ten clinicians wrote it for type 2 diabetes, not for weight, with medical writing funded by Novo Nordisk; a 2026 obesity study notes there are no obesity-specific switching guidelines45. So it is a common timing, not label guidance.

The half-lives explain why no long gap is needed. A half-life is the time the body takes to clear half of a drug. Liraglutide's is about 13 hours1, so a day after the last Saxenda dose a little over a quarter of it is left, after two days about 8% and after three days about 2%. That is arithmetic on the label's number, not a waiting time any study set. Semaglutide works the other way: its half-life is about one week, the first Wegovy dose peaks in the blood one to three days after the shot, and the weekly doses stack until the level evens out2.

Try it

How Semaglutide builds up

An estimate from a half-life of about 6.9 days, one dose a week for four weeks. The shape of the level, not a measurement.

Try your own scheduleSemaglutide in the library

The last Saxenda dose halving every 13 hours: a little over a quarter left after one day, about 8% after two, about 2% after three; the first Wegovy shot, given the next day, peaks in the blood one to three days later
Saxenda fades within about three days while the first Wegovy shot builds; the two curves cross in the first days.
  1. Your prescriber sets the plan and the dates: neither label gives a schedule for the switch12.
  2. Write down the date and strength of your last daily Saxenda dose, so the start date and any gap are clear.
  3. The two drugs do not overlap: both labels advise against using either with another GLP-1 drug12.
  4. The start date your prescriber gives is often the day the next Saxenda dose would have been due, the timing the diabetes consensus describes4.
  5. On the label, the first Wegovy dose is 0.25 mg once weekly, for weeks 1 to 42.
  6. The label's routine after that: once a week on the same day, at any time of day, with or without meals, in the belly, thigh or upper arm2.
  7. The label's schedule steps up every four weeks: 0.5 mg, 1 mg, 1.7 mg, then a maintenance dose from week 17. When a step is hard to tolerate, the label lets the prescriber hold it four more weeks2.

In PepVault, finishing the Saxenda protocol keeps every daily dose on file, and a new Wegovy protocol set to once weekly gets its own dose time and reminder, so the nudge moves from every day to shot day. Set reminders in PepVault

Do you start Wegovy at 0.25 mg after Saxenda?

On the label, yes. Wegovy's starting dose is 0.25 mg once weekly for four weeks for every approved use, and the label makes no exception for someone coming from another GLP-1 drug2. The climb exists to lower the risk of stomach side effects, and the label gives no shorter climb for time already spent on Saxenda2. Our Wegovy and Ozempic dosage guide prints every step and the maintenance doses, and the titration planner lays the weeks out on a calendar.

The diabetes consensus starts at the lowest dose too when the old drug caused stomach trouble or was below its top dose. For someone on the old drug's top dose, its authors describe a higher start from their own diabetes practice and say themselves that it is not in accordance with the label4; Wegovy's label start stays 0.25 mg2. They also note that semaglutide reaches only about 75% of its steady level after two weekly doses, so a faster climb lands before the level has caught up4.

So the first weeks on 0.25 mg can feel weaker than 3 mg of Saxenda did: that is the ladder, not the drug failing, and the Italian switching cohort below saw exactly that slow start5.

What happened to weight after switching from liraglutide?

Two small published studies followed people who moved from liraglutide to semaglutide, only one of them in obesity without diabetes. Weight change is counted from the day semaglutide started, on top of what was lost on liraglutide.

StudyWhoWhat changedWhat it found
Milani 2026, retrospective cohort5258 adults with overweight or obesity and no diabetes at two Italian obesity clinics (Latina and Rome), 211 of them with follow-up data; 62 came from liraglutide (median top dose 1.8 mg a day)5Weekly semaglutide, doses set by tolerance and cost; median dose about 1 to 1.2 mg5Switchers against people new to the drug class, median weight change: −2.7% vs −6.0% at 2 to 4 months, −7.5% vs −11.0% at 5 to 8 months, −13.3% vs −13.6% at 9 to 15 months, the last with only 17 switchers still followed5
Iijima 2023, randomised632 adults in Japan with type 2 diabetes on liraglutide 0.6 or 0.9 mg a daySwitched to semaglutide 0.25 mg for 4 weeks, then 0.5 mg, or to dulaglutide; 26 weeks6Semaglutide: weight −2.6 kg, HbA1c (the three-month blood sugar average) down 0.42 points; dulaglutide: no weight change6
Median weight change in Milani 2026: at 2 to 4 months −2.7% for switchers against −6.0% for people new to the class; at 5 to 8 months −7.5% against −11.0%; at 9 to 15 months −13.3% against −13.6%
People coming from liraglutide lost less in the first months and caught up by a year (medians, one Rome cohort).

In the Italian cohort the switchers started slower and caught up: by the 9 to 15 month visit their weight loss matched that of people starting fresh, though by then few were left to count5. The authors point to the gradual climb leaving switchers under-dosed in the first months, along with the plateau that often follows a first treatment, and they call for attention to the dose after a switch5. Most of the cohort never reached the 2.4 mg maintenance dose, so these numbers sit below what the label's full schedule aims for5.

PepVault's weight log is one line across both drugs, so the Saxenda months and the first Wegovy months sit on the same chart, slow start included. Track your weight in PepVault

Do side effects come back after the switch?

Often for a while. In STEP 8, stomach side effects were about as common on either drug, 84.1% on semaglutide and 82.7% on liraglutide3, so a body used to Saxenda is not used to every dose of Wegovy. In the Japanese switching trial, 12 of 16 people moved to semaglutide reported a side effect over 26 weeks, most often a lower appetite with a changed sense of taste, and one stopped because of severe vomiting and weight loss6.

The diabetes consensus authors tell patients that stomach effects after a switch are usually short-lived, and that smaller portions and less fat in meals help, along with a slow climb4; the Wegovy label notes that the drug slows how fast the stomach empties2. Each step-up on Wegovy can bring them back for a few days; the label's answer to a step that is hard to tolerate is waiting four more weeks before the next one2.

Commonly reported: appetite drops further on Wegovy than it did on Saxenda, and nausea comes back in the first days after the early weekly shots and after each step-up, then settles.

When to get help Stomach pain that is severe or will not go away, sometimes reaching the back, is a reason to contact a clinician the same day: both labels list it as a sign of pancreatitis12.

What if a gap opens between Saxenda and Wegovy?

A delay, such as a prescription that takes a week to fill, runs into each label's missed-dose rule:

  • Saxenda: a missed day is simply skipped and the next scheduled dose taken, never a double dose. After more than 3 days without it, the label restarts Saxenda at 0.6 mg a day and climbs again1.
  • Wegovy: one missed weekly dose is taken if the next is more than 2 days away, otherwise skipped. After two or more missed doses in a row, the label restarts the climb at a lower dose2.
  • Going back the other way: semaglutide stays in the blood for about 5 to 7 weeks after the last Wegovy dose2, so a move from Wegovy to Saxenda is a different calculation, and no label times it.

The missed-dose tool walks the Wegovy rule against your own dates. If Saxenda is still on hand during a delay, whether to bridge with it is a question for the prescriber, since the label's restart rule applies after three days off.

Track it in the app

Sources

  1. Novo Nordisk. SAXENDA (liraglutide) injection, prescribing information. DailyMed, version 22, June 15, 2026. dailymed.nlm.nih.gov
  2. Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information. DailyMed, version 19, June 30, 2026. dailymed.nlm.nih.gov
  3. Rubino DM et al.; STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022. PubMed 35015037
  4. Jain AB et al. Switching between GLP-1 receptor agonists in clinical practice: expert consensus and practical guidance. Int J Clin Pract. 2021. PubMed 32975890
  5. Milani I et al. Real-world semaglutide in obesity cohort: effectiveness, safety and persistence across sex, BMI, and prior GLP-1RA treatment. Front Endocrinol (Lausanne). 2026. PubMed 42582375
  6. Iijima T et al. Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: a randomized controlled trial. J Diabetes Investig. 2023. PubMed 36871272
  7. Qaseem A et al.; Clinical Guidelines Committee of the American College of Physicians. Pharmacologic treatments with lifestyle modifications in nonpregnant adults with overweight or obesity in outpatient settings: a living clinical guideline (April 2026). Ann Intern Med. 2026. PubMed 42296496

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo